Part,  Chapter, Paragraph

 1   II,     5.  1.  2|          always have to be read and discussed “simultaneously”. Difficulties
 2   II,     5.  5.  3|          Similar to the limitations discussed for prevalence studies,
 3   II,     5.  8.  3| methodologies. Although, as already discussed, comparisons between countries
 4   II,     6.  3.  1|            For many of the diseases discussed in this report, national
 5   II,     6.  3.  7|            as a threat in 2005, are discussed here below. The quality
 6   II,     9.  1.  2|             childhood and these are discussed elsewhere in this Report (
 7   II,     9.  1.  2|         TOPFA in the population, as discussed in detail elsewhere (EUROCAT,
 8  III,    10.  2.  1|            micronutrients have been discussed as potentially critical
 9  III,    10.  2.  1|          for dealing with FBDG were discussed at the above-mentioned EFSA’
10  III,    10.  2.  4|             and complex diseases is discussed mainly in the clinical setting.
11  III,    10.  3.  2|      Brominated flame retardant are discussed in the following section
12  III,    10.  4.  2|             other of the previously discussed zoonotic pathogens such
13  III,    10.  4.  2|          2006).~ ~PFOS is currently discussed as candidate for inclusion
14  III,    10.  4.  2|       dose-response data. EFSA then discussed the data requirements for
15  III,    10.  4.  2|         reach such a conclusion are discussed in detail in the present
16  III,    10.  5.  1|           overall living setting is discussed first, before more details
17  III,    10.  5.  1|   settlement areas is presented and discussed.~ ~
18  III,    10.  5.  2|             different than the data discussed in the introduction above,
19  III,    10.  5.  2|            The results and findings discussed in this chapter therefore
20  III,    10.  6.  2|             job conditions has been discussed in terms of physical demands
21   IV,    11.  1.  1|      training of personnel are then discussed, including health care facilities,
22   IV,    11.  1.  5|            patient safety, which is discussed here below. The lack of
23   IV,    11.  2.  1|            hospital utilization, as discussed elsewhere (Figueras et al,
24   IV,    11.  3    |            hospital beds, have been discussed in the previous section,
25   IV,    11.  5.  4|           of European citizens have discussed organ donation within the
26   IV,    11.  5.  4|          correlation between having discussed it within the family and
27   IV,    12.  1    |           improved. The results are discussed during the two yearly meetings